Discovery Labs Provides Commercial Update for SURFAXIN, AFECTAIR

Discovery Laboratories

today reports a commercial update for SURFAXIN® and AFECTAIR®.  The Company has initiated commercial launch activities for both products by training and deploying its newly-formed commercial and medical affairs organizations with the goal of securing hospital formulary acceptance for SURFAXIN, expected to be commercially available in the second quarter of 2013, and adoption of AFECTAIR with an anticipated product availability in December 2012. As the Company continues to make progress in its launch readiness efforts, Discovery Labs has: Held its first national meeting to welcome and complete the training of its newly-hired field sales force, national accounts team and medical science liaison team, Deployed its field force with the primary objective of gaining hospital formulary acceptance for SURFAXIN and adoption of AFECTAIR,  Executed or is finalizing group purchasing organization and national account contracts, Continues to manufacture SURFAXIN at a commercial scale as it has for several years, Established supply chain distribution and warehouse arrangements, Enhanced its quality control and assurance infrastructure with additional hiring of highly-qualified